Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer. P & T : a peer-reviewed journal for formulary management [P T] Journal article

Ixabepilone (Ixempra) is a member of a new class of cytotoxic agents, the epothilones. Epothilones promote tubulin polymerization in vitro and demonstrate antitumor activity. This article reviews the preclinical and clinical data that have led to the approval of ixabepilone for patients with locally advanced or metastatic breast cancer for whom anthracycline and taxane treatments have failed.

P & T : a peer-reviewed journal for formulary management [P T]